Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 2/20 | 0.55 |
| ▸ | BCR | P11274 | 2/20 | 0.55 |
| ▸ | ACVR1 | Q04771 | 7/20 | 0.53 |
| ▸ | JAK2 | O60674 | 2/20 | 0.46 |
| ▸ | JAK3 | P52333 | 1/20 | 0.46 |
| ▸ | AURKA | O14965 | 6/20 | 0.43 |
| ▸ | AURKB | Q96GD4 | 6/20 | 0.43 |
| ▸ | KDR | P35968 | 2/20 | 0.42 |
| ▸ | CDK1 | P06493 | 1/20 | 0.42 |
| ▸ | IGF1R | P08069 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5090825 | 0.97 | ABL1 (0.56) | ABL1BCRACVR1JAK2JAK3 | |
| SCHEMBL5096947 | 0.93 | ACVR1 (0.62) | ABL1BCRACVR1JAK2JAK3 | |
| SCHEMBL4629179 | 0.92 | ABL1 (0.55) | ABL1BCRACVR1JAK2JAK3 | |
| SCHEMBL4628172 | 0.91 | ABL1 (0.52) | ABL1BCRACVR1JAK2JAK3 | |
| SCHEMBL4629155 | 0.91 | ABL1 (0.52) | ABL1BCRACVR1JAK2JAK3 | |
| SCHEMBL5090902 | 0.90 | ABL1 (0.58) | ABL1BCRACVR1JAK2JAK3 | |
| SCHEMBL5097306 | 0.90 | ABL1 (0.54) | ABL1BCRACVR1JAK2JAK3 | |
| SCHEMBL4629212 | 0.88 | ACVR1 (0.50) | ABL1BCRACVR1JAK2JAK3 | |
| SCHEMBL4629853 | 0.87 | ABL1 (0.55) | ABL1BCRACVR1JAK2JAK3 | |
| SCHEMBL4629079 | 0.85 | ABL1 (0.54) | ABL1BCRACVR1JAK2JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080242667-A1 | Pyrimidinyl-Pyrazole Inhibitors of Aurora Kinases | SMITHKLINE BEECHAM CORPORATION | 2008-10-02 | — | — | US | claimed |
| EP-1917258-A2 | PYRIMIDINYL-PYRAZOLE INHIBITORS OF AURORA KINASES | SmithKline Beecham Corporation (US) | 2008-05-07 | — | — | EP | claimed |
| WO-2007024843-A2 | PYRIMIDINYL-PYRAZOLE INHIBITORS OF AURORA KINASES | SMITHKLINE BEECHAM CORPORATION (US) | 2007-03-01 | — | — | WO | claimed |
| US-20080242667-A1 | Pyrimidinyl-Pyrazole Inhibitors of Aurora Kinases | SMITHKLINE BEECHAM CORPORATION | 2008-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080242667-A1 | Pyrimidinyl-Pyrazole Inhibitors of Aurora Kinases | AURKA, AURKC, PLK1 | ABL1 55/4885BCR 1018/4885ACVR1 1609/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.